BRI3BP Polyclonal Antibody (E-AB-53455)
For research use only.
| Verified Samples |
Verified Samples in WB: RAW264.7, K562 Verified Samples in IHC: Human cervical cancer, Human tonsil |
| Dilution | WB 1:500-1:2000, IHC 1:30-1:150 |
| Isotype | IgG |
| Host | Rabbit |
| Reactivity | Human, Mouse |
| Applications | WB, IHC |
| Clonality | Polyclonal |
| Immunogen | Synthetic peptide of human BRI3BP |
| Abbre | BRI3BP |
| Synonyms | BNAS1, BRI3 binding protein, BRI3-binding protein, BRI3B, Bri3bp, Cervical cancer 1 proto oncogene binding protein KG19, Cervical cancer 1 proto-oncogene-binding protein KG19, HCCR-2, HCCR1, HCCRBP-1, I3 binding protein, I3-b, cervical cancer oncogene binding protein |
| Swissprot | |
| Calculated MW | 28 kDa |
| Observed MW |
Refer to figures
The actual band is not consistent with the expectation.
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
| Cellular Localization | Mitochondrion outer membrane. |
| Concentration | 0.9 mg/mL |
| Buffer | Phosphate buffered solution, pH 7.4, containing 0.05% stabilizer and 50% glycerol. |
| Purification Method | Antigen affinity purification |
| Research Areas | Cancer, Cell Biology |
| Conjugation | Unconjugated |
| Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
| Shipping | The product is shipped with ice pack,upon receipt,store it immediately at the temperature recommended. |
| background | BRI3BP (BRI3 binding protein), also known as BNAS1, HCCR-1, I3-binding protein or cervical cancer 1 proto-oncogene-binding protein KG19, is a 251 amino acid multi-pass membrane protein. Though widely expressed, BRI3BP is found at highest levels in brain, kidney and liver where it localizes to the endoplasmic reticulum (ER) and is involved in ER structural dynamics and mitochondrial viability. Possessing pro-apoptotic properties and the ability to potentiate drug-induced apoptosis, BRI3BP overexpression has been shown to enhance caspase-3 and mitochondrial cytochrome c release in etoposide-treated human embryonic kidney 293T cells. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
Unconjugated
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
